Marianne Dibrino

Array ( [id] => 9491048 [patent_doc_number] => 20140141455 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-05-22 [patent_title] => 'METHODS OF ASSAYING VACCINE POTENCY' [patent_app_type] => utility [patent_app_number] => 14/053012 [patent_app_country] => US [patent_app_date] => 2013-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 25600 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14053012 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9204935 [patent_doc_number] => 20140004112 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-01-02 [patent_title] => 'Therapeutic Peptides' [patent_app_type] => utility [patent_app_number] => 14/025573 [patent_app_country] => US [patent_app_date] => 2013-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 40 [patent_figures_cnt] => 40 [patent_no_of_words] => 27120 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14025573 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13151859 [patent_doc_number] => 10092634 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-10-09 [patent_title] => UBE2T peptides and vaccines containing the same [patent_app_type] => utility [patent_app_number] => 14/400169 [patent_app_country] => US [patent_app_date] => 2013-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 10 [patent_no_of_words] => 31466 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14400169 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17937054 [patent_doc_number] => 11471486 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-18 [patent_title] => Selective and controlled expansion of educated NK cells [patent_app_type] => utility [patent_app_number] => 14/425614 [patent_app_country] => US [patent_app_date] => 2013-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 13 [patent_no_of_words] => 9266 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 130 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14425614 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11561905 [patent_doc_number] => 09624479 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-04-18 [patent_title] => 'Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes' [patent_app_type] => utility [patent_app_number] => 13/975404 [patent_app_country] => US [patent_app_date] => 2013-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 27 [patent_no_of_words] => 16088 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 136 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13975404 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10340692 [patent_doc_number] => 20150225697 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-13 [patent_title] => 'NATURAL KILLER CELLS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/421059 [patent_app_country] => US [patent_app_date] => 2013-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 34 [patent_no_of_words] => 73244 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14421059 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10306545 [patent_doc_number] => 20150191546 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-09 [patent_title] => 'MONOCLONAL ANTIBODIES FOR USE IN DIAGNOSIS AND THERAPY OF CANCERS AND AUTOIMMUNE DISEASE' [patent_app_type] => utility [patent_app_number] => 14/413833 [patent_app_country] => US [patent_app_date] => 2013-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 35009 [patent_no_of_claims] => 61 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14413833 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14945781 [patent_doc_number] => 10434136 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-08 [patent_title] => Powerful MHC-class II peptides derived from survivin [patent_app_type] => utility [patent_app_number] => 13/931413 [patent_app_country] => US [patent_app_date] => 2013-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 36181 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13931413 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10006781 [patent_doc_number] => 09050279 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-06-09 [patent_title] => 'Compositions and methods using recombinant MHC molecules for the treatment of stroke' [patent_app_type] => utility [patent_app_number] => 13/924275 [patent_app_country] => US [patent_app_date] => 2013-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 60 [patent_no_of_words] => 54823 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 227 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13924275 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10398225 [patent_doc_number] => 20150283233 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-10-08 [patent_title] => 'Compositions and Methods for Enhancing Immune Responses' [patent_app_type] => utility [patent_app_number] => 14/408159 [patent_app_country] => US [patent_app_date] => 2013-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 24198 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14408159 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9081068 [patent_doc_number] => 20130266598 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-10-10 [patent_title] => 'Identification, Optimization And Use Of Cryptic HLA-B7 Epitopes For Immunotherapy' [patent_app_type] => utility [patent_app_number] => 13/920003 [patent_app_country] => US [patent_app_date] => 2013-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 9380 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13920003 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11582913 [patent_doc_number] => 09637538 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-05-02 [patent_title] => 'Anti-HLA monoclonal chimeric immunoglobulin, process and kit employing such a monoclonal chimeric immunoglobulin' [patent_app_type] => utility [patent_app_number] => 13/869477 [patent_app_country] => US [patent_app_date] => 2013-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 16 [patent_no_of_words] => 11134 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13869477 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9134330 [patent_doc_number] => 20130295044 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-07 [patent_title] => 'NATURAL KILLER CELLS WITH ENHANCED IMMUNE RESPONSE' [patent_app_type] => utility [patent_app_number] => 13/865762 [patent_app_country] => US [patent_app_date] => 2013-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 37 [patent_no_of_words] => 16593 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13865762 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9042747 [patent_doc_number] => 20130245385 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-09-19 [patent_title] => 'SELECTIVE ANTI-HLA ANTIBODY REMOVAL DEVICE AND METHODS OF PRODUCTION AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 13/860897 [patent_app_country] => US [patent_app_date] => 2013-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 35 [patent_no_of_words] => 31058 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13860897 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9035051 [patent_doc_number] => 20130237689 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-09-12 [patent_title] => 'SOLUBLE HLA CLASS II COMPLEXES AND METHODS OF PRODUCTION AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 13/859811 [patent_app_country] => US [patent_app_date] => 2013-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 19481 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13859811 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11922704 [patent_doc_number] => 09790273 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-10-17 [patent_title] => 'Anti-HLA-B*27 antibodies and uses thereof' [patent_app_type] => utility [patent_app_number] => 13/855448 [patent_app_country] => US [patent_app_date] => 2013-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24673 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13855448 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10729847 [patent_doc_number] => 20160075996 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-17 [patent_title] => 'METHOD FOR PRODUCING NK CELL-ENRICHED BLOOD PREPARATION' [patent_app_type] => utility [patent_app_number] => 14/780394 [patent_app_country] => US [patent_app_date] => 2013-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 14747 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14780394 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9901024 [patent_doc_number] => 20150056225 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-02-26 [patent_title] => 'HLA Class II Deficient Cells, HLA Class I Deficient Cells Capable of Expressing HLA Class II Proteins, and Uses Thereof' [patent_app_type] => utility [patent_app_number] => 14/391328 [patent_app_country] => US [patent_app_date] => 2013-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 12650 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14391328 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8939505 [patent_doc_number] => 20130189302 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-07-25 [patent_title] => 'IMMUNOTHERAPEUTIC METHOD USING ARTIFICIAL ADJUVANT VECTOR CELLS THAT CO-EXPRESS CD1D AND TARGET ANTIGEN' [patent_app_type] => utility [patent_app_number] => 13/834096 [patent_app_country] => US [patent_app_date] => 2013-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 18722 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13834096 [rel_patent_id] =>[rel_patent_doc_number] =>)